Healthcare businesses are speeding up R&D in order to develop effective medications that will help minimise the morbidity and mortality linked with coronavirus. Despite the fact that demand for excipients and active pharmaceutical ingredients (APIs) has increased during the pandemic, delayed treatment and missed medical visits are harming sales of Microcrystalline Cellulose (MCC). In...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian